Current Oncology, 2023 Fluoropyrimidine chemotherapy is associated with interpatient variability in toxicity. A major contributor to unpredictable and severe toxicity relates to single nucleotide variation (SNV) in dihydropyrimidine dehydrogenase (DPYD), the rate-limiting ...
Theodore J. Wigle +4 more
doaj +1 more source
Swiss Medical Weekly, 2020 Fluoropyrimidines (FPs), mainly 5-fluorouracil (5-FU) and its oral prodrug capecitabine (Cap), remain the backbone of the treatment of many different solid tumors.
Seid Hamzic +6 more
doaj +1 more source
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines [PDF]
, 2021 5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity
Borobia Pérez, Alberto M. +36 more
core +1 more source
TEYSUNO: FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH DISSEMINATED GASTRIC CANCER
Медицинский совет, 2017 Gastric cancer is one of the leading causes of death among all cancers in Russia. Progression-free and overall survival cannot be drastically changed by current therapeutic approaches. There is a strong need in new drugs for that disease.
O. O. GORDEEVA, M. E. ABRAMOV, A. N. LUD
doaj +1 more source
Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation
Медицинский совет, 2018 Today, the researchers continue the search for the most optimal regimens of drug therapy for metastatic colorectal cancer (mCRC) which are supposed to increase progression-free survival (PFS) and overall survival (OS), improve patient quality of life ...
A. D. Darenskaya +2 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Introduction: Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD gene, is the rate-limiting enzyme responsible for fluoropyrimidine (FP) catabolism.
Georgia Ragia +17 more
doaj +1 more source
Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines [PDF]
, 2018 The correlation between DPYD*9A (c.85T>C) genotype and dihydropyrimidine dehydrogenase (DPD) deficiency clinical phenotype is controversial. Reference laboratories either did not perform DPYD*9A genotyping or have stopped DPYD*9A genotyping and limited ...
Jones, Vanessa +34 more
core +1 more source
Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
Brazilian Journal of Oncology, 2021 The implementation, current status and future perspectives of the pharmacogenetics/genomics (PGx) testing program developed at Instituto Nacional de Cancer (INCA) are presented. Initial selection of drug-gene pairs for PGx testing was based on clinically-
Guilherme Suarez-Kurtz
doaj +1 more source
Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options? [PDF]
Clinical Pharmacology & Therapeutics, 2020 Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although most often well tolerated, severe toxicity is encountered in ~ 20–30% of the patients. Individualized dosing for these patients can reduce the incidence of severe fluoropyrimidine‐related toxicity.
Knikman, J.E. +5 more
openaire +3 more sources
A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update [PDF]
, 2008 At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of ...
Middleton, M. (Mark) +15 more
core +1 more source